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Diegem, Belgium; Santa Clara, California; Melbourne, Victoria, Australia; Milan, Italy;
New York, New York; and São Paulo, BrazilObjectives The aim of this study was to evaluate 1-year clinical outcomes of diabetic patients treated
with the Absorb bioresorbable vascular scaffold (BVS).
Background Clinical outcomes of diabetic patients after BVS implantation have been unreported.
Methods This study included 101 patients in the ABSORB Cohort B trial and the ﬁrst consecutive 450
patients with 1 year of follow-up in the ABSORB EXTEND trial. A total of 136 diabetic patients were
compared with 415 nondiabetic patients. In addition, 882 diabetic patients treated with everolimus-
eluting metal stents (EES) in pooled data from the SPIRIT trials (SPIRIT FIRST [Clinical Trial of the Abbott
Vascular XIENCE V Everolimus Eluting Coronary Stent System], SPIRIT II [A Clinical Evaluation of the XIENCE
V Everolimus Eluting Coronary Stent System], SPIRIT III [Clinical Trial of the XIENCE V Everolimus Eluting
Coronary Stent System (EECSS)], SPIRIT IV Clinical Trial [Clinical Evaluation of the XIENCE V Everolimus
Eluting Coronary Stent System]) were used for the comparison by applying propensity score matching.
The primary endpoint was a device-oriented composite endpoint (DoCE), including cardiac death, target
vessel myocardial infarction, and target lesion revascularization at 1-year follow-up.
Results The cumulative incidence of DoCE did not differ between diabetic and nondiabetic patients
treated with the BVS (3.7% vs. 5.1%, p ¼ 0.64). Diabetic patients treated with the BVS had a similar
incidence of the DoCE compared with diabetic patients treated with EES in the matched study group
(3.9% for the BVS vs. 6.4% for EES, p ¼ 0.38). There were no differences in the incidence of deﬁnite or
probable scaffold/stent thrombosis (0.7% for both diabetic and nondiabetic patients with the BVS; 1.0%
for diabetic patients with the BVS vs. 1.7% for diabetic patients with EES in the matched study group).
Conclusions In the present analyses, diabetic patients treated with the BVS showed similar rates of
DoCEs compared with nondiabetic patients treated with the BVS and diabetic patients treated with
EES at 1-year follow-up. (ABSORB Clinical Investigation, Cohort B; NCT00856856; ABSORB EXTEND
Clinical Investigation; NCT01023789; Clinical Trial of the Abbott Vascular XIENCE V Everolimus Eluting
Coronary Stent System [SPIRIT FIRST]; NCT00180453; A Clinical Evaluation of the XIENCE V Everolimus
Eluting Coronary Stent System [SPIRIT II]; NCT00180310; Clinical Trial of the XIENCE V Everolimus
Eluting Coronary Stent System [EECSS] [SPIRIT III]; NCT00180479; Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System [SPIRIT IV Clinical Trial]; NCT00307047). (J Am Coll Cardiol
Intv 2014;7:482–93) ª 2014 by the American College of Cardiology Foundation
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483A dramatic increase in the incidence of diabetes mellitus has XIENCE V Everolimus Eluting Coronary Stent System],
been recognized as a serious worldwide issue (1). Diabetes
causes systemic microvascular and macrovascular complica-
tions including coronary artery disease (CAD) that ulti-
mately contributes to cardiovascular mortality (2,3).See page 494
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and Acronyms
ARC = Academic Research
Consortium
BMS = bare-metal stent(s)
BVS = bioresorbable vascular
scaffold
CAD = coronary artery
disease
DES = drug-eluting stent(s)
DoCE = device-oriented
composite endpoint
EES = everolimus-eluting
metal stent(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
PoCE = patient-oriented
composite endpoint
PS = propensity score
ST = scaffold/stent
thrombosis
TLR = target lesion
revascularizationDrug-eluting stents (DES) considerably reduce the need
for repeat revascularization in diabetic patients compared
with bare-metal stents (BMS) (4). The presence of diabetes,
however, has still been associated with an increased risk of
adverse clinical events after percutaneous coronary interven-
tion (PCI) with DES (5,6). Although newer generation DES
have generally shown better long-term outcomes compared with
ﬁrst-generation DES (7–9), a pooled analysis of 4 randomized
trials using newer generation everolimus-eluting metal stents
(EES) showed a marked attenuation of beneﬁcial effects
compared with ﬁrst-generation paclitaxel-eluting stents in a
subset of diabetic patients (10). The best type of DES for
the treatment of diabetic patients remains unclear.
Bioresorbable vascular scaffolds (BVSs) are a novel
approach to the treatment of CAD in that they provide
transient vessel support and drug delivery to the vessel wall
(11). The ABSORB Cohort B trial investigating the current
generation of the everolimus-eluting BVS system (Absorb
BVS, Abbott Vascular, Santa Clara, California) has shown an
acceptable incidence rate of major adverse cardiac events
(10.0%) without any scaffold thrombosis up to 3 years of
follow-up (12).
To date, clinical outcomes of diabetic patients treated
with the Absorb BVS have not been speciﬁcally described.
Thus, the aim of this study was: 1) to assess the 1-year
clinical outcomes of diabetic patients treated with the
Absorb BVS compared with nondiabetic patients, using
pooled individual data of the ABSORB Cohort B and the
ABSORB EXTEND trials; and 2) to compare the 1-year
clinical outcomes of diabetic patients treated with the
Absorb BVS with that of diabetic patients treated with EES,
using propensity-score (PS) matching of pooled data from
the SPIRIT trials (SPIRIT FIRST [A Clinical Trial of the
Abbott Vascular XIENCE V Everolimus Eluting Coronary
Stent System], SPIRIT II [A Clinical Evaluation of theFrom the *Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands;
yDepartment of Cardiology, Fujita Health University Hospital, Toyoake, Japan;
zInstitut Cardiovasculaire Paris Sud, Massy, France; xKrishna Heart Institute,
Ahmedabad, India; jjFortis Escorts Heart Institute, New Delhi, India; {Abbott
Vascular, Diegem, Belgium; #Abbott Vascular, Santa Clara, California; **Cardiovas-
cular Research Center, St. Vincent’s Hospital, Melbourne, Victoria, Australia;
yyCentro Cardiologico Monzino, IRCCS, University of Milan, Milan, Italy;
zzColumbia University Medical Center/New York–Presbyterian Hospital and Car-
diovascular Research Foundation, New York, New York; and the xxInstituto Dante
Pazzanese de Cardiologia, São Paulo, Brazil. The ABSORB Cohort B, the ABSORB
EXTEND, the SPIRIT FIRST, the SPIRIT II, the SPIRIT III, and the SPIRIT IVSPIRIT III [Clinical Trial of the XIENCE V Everolimus
Eluting Coronary Stent System (EECSS)], SPIRIT IV
Clinical Trial [Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System]).Methods
Study population. We included all patients enrolled in the
ABSORB Cohort B trial and the ﬁrst consecutive 450 pa-
tients with 1 year of follow-up in the ABSORB EXTEND
trial. As enrollment in the ABSORB EXTEND trial was
completed on October 2, 2013, clinical follow-up is currently
ongoing, and the data for this analysis were obtained from
an interim data cutoff date of
December 3, 2012. The details of
these 2 trials have been described
elsewhere (13,14). In brief, both
trials were prospective, multi-
center, single-arm studies assess-
ing the safety and feasibility of
the Absorb BVS. Patients older
than 18 years of age who have 1
or 2 de novo lesions located in
a different major epicardial vessel
were enrolled. Target lesions must
have a visually estimated stenosis
of 50% and <100% and a
Thrombolysis In Myocardial In-
farction ﬂow grade of 1. Major
exclusion criteria were patients
presenting with an acute myocar-
dial infarction (MI), left ventricu-
lar ejection fraction <30%, renal
insufﬁciency, aorto-ostial lesions,
left main coronary artery lesions,
total occlusions, heavily calciﬁed
lesions, and lesions with visible
thrombus.
For the current analysis, dia-betic patients treated with the XIENCE V EES (Abbott
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484historical controls. The details of all these SPIRIT trials
were also described previously (7,8,15,16). Of note, major
inclusion and exclusion criteria of these trials were similar to
those of the ABSORB Cohort B and the ABSORB
EXTEND trials, whereas inclusion criteria of the SPIRIT
IV trial were more liberal than the other trials by permitting
enrollment of patients with complex lesions that were
deﬁned as a maximum of 3 target lesions in 3 separate major
epicardial coronary arteries, a maximum of 2 target lesions in
a single coronary artery, an ostial right coronary artery lesion,
or bifurcation lesions in which the side branch was 2 mm
in diameter or the ostium of the side branch was >50%
stenosed (8). The features of the aforementioned trials are
summarized in Online Table 1.
All of these trials were sponsored and funded by
Abbott Vascular. The research ethics committee of each
participating institution approved the protocol, and all
enrolled patients provided written informed consent before
inclusion.
Study devices and treatment procedure. The details of
study devices and diabetic treatment are presented in the
Online Appendix. Lesions were treated using standard
interventional techniques, with mandatory pre-dilation and
scaffold/stent implantation at a pressure not exceeding the
burst pressure rate. Post-dilation was left to the discretion of
the operator and only permitted with balloons sized to ﬁt
within the boundaries of the scaffold/stent. Patients were
treated with aspirin 80 mg pre-procedurally. A 300-mg
loading dose of clopidogrel between 6 and 24 h before the
procedure was required. After the index procedure, aspirin
75 or 80 mg daily throughout the duration of the trial and
clopidogrel 75 mg daily for a minimum of 6 months should
be administered except for the SPIRIT FIRST trial (a
minimum of 3 months for clopidogrel).
Deﬁnition of clinical outcomes. In the present analysis, the
primary clinical outcome was assessed by a device-oriented
composite endpoint (DoCE), which is also known as target
lesion failure at 1 year after the index procedure. This was
deﬁned as a composite of cardiac death, target vessel MI, or
ischemia-driven target lesion revascularization (TLR). Sec-
ondary clinical outcome was a patient-oriented composite
endpoint (PoCE) that was deﬁned as a composite of all-
cause death, all MIs, or any repeat revascularization. These
classiﬁcations of outcome measures were on the basis of the
Academic Research Consortium (ARC) deﬁnitions (17).
In the event of a death that could not be attributed to
another cause, it was considered as a cardiac death. The
incidence of scaffold/stent thrombosis (ST) according to the
ARC criteria is also reported up to 1 year of follow-up.
Per-protocol MI was deﬁned either as the development of
new Q waves or as an increase in the creatine kinase level to
greater than twice the upper limit of normal, accompanied
by an increased level of creatine kinase-myocardial band
(18). Notably, this deﬁnition of per-protocol MI wasconsistently applied in all trials used for the present analysis.
All clinical outcomes were adjudicated by an independent
clinical events committee.
Clinical follow-up and source document veriﬁcation. Except
for the studies with planned angiographic follow-up at
1 year, patients were clinically followed by their visits to the
outpatient clinic or by telephone calls. In the ABSORB
Cohort B, the SPIRIT FIRST, the SPIRIT II, the SPIRIT
III, and the SPIRIT IV trials, source document veriﬁcation
was performed in 100% of patients through 1-year follow-
up. In the ABSORB EXTEND trial, source document
veriﬁcation was routinely performed in 100% of patients
through 30-day follow-up, subsequently in a random 20% of
patients, and in 100% of all reported events for the
remaining follow-up period.
Statistical analysis. For the present analyses, individual data
were pooled on a patient-level basis. Continuous variables
are expressed as mean  SD and categorical variables are
presented as proportion (%). Comparisons were performed
by the t test for continuous variables and by chi-square or
Fisher exact test when the Cochran rule is not met for
categorical variables. Time-to-event variables are presented
as Kaplan-Meier curves. Subjects were counted only once for
a composite endpoint in hierarchical order, whereas the
incidence of the components and ST events are shown in
nonhierarchical order. PS matching was applied to compare
1-year clinical outcomes of diabetic patients treated with the
BVS and those treated with EES. The details of PS
matching are presented in the Online Appendix. Consid-
ering the larger number of diabetic patients treated with
EES (N ¼ 882) compared with that of diabetic patients
treated with the BVS (N ¼ 136), a 1:2 matching
(BVS:EES) was performed in this study. A 2-sided p value
<0.05 was considered statistically signiﬁcant.Results
Study population. A ﬂow diagram of this study is shown in
Figure 1. We included 101 patients in the ABSORB Cohort
B trial and 450 patients in the ABSORB EXTEND trial.
All patients were treated with the Absorb BVS and were
classiﬁed as either diabetic (n ¼ 136) or nondiabetic (n ¼
415). For diabetic patients treated with EES as a control
group, we ﬁrst excluded the patients with complex lesions in
the SPIRIT IV trial (n ¼ 128). In addition, 2 patients in the
SPIRIT III trial and 26 patients in the SPIRIT IV trial were
excluded because of the lack of 1-year follow-up data. A
total of 882 diabetic patients treated with EES in a pooled
study group from the SPIRIT trials was used for the com-
parisons between the BVS and EES.
Of these diabetic patients, the PS was not assessable for
11 of 136 patients in the BVS group and 221 of 882 patients
in the EES group because of missing baseline characteristics
Figure 1. Flow Diagram of This Study
Asterisk indicates diabetic patients in the SPIRIT IV trial after excluding those with complex lesions, deﬁned as triple-vessel treatment, 2 lesions per vessel treatment,
lesions involving ostial right coronary artery lesions, or bifurcations lesions in which the side branch was 2 mm in diameter or the ostium of the side branch was
>50% stenosed. BVS ¼ bioresorbable vascular scaffold; EES ¼ everolimus-eluting metal stent(s).
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485necessary to compute the PS. By applying the aforemen-
tioned methodology of PS matching, 23 patients in the BVS
group and 489 patients in the EES group were excluded
during the matching process. Consequently, there were 102
diabetic patients in the BVS group matched with 172 dia-
betic patients in the EES group for the comparative analyses.
Comparisons between diabetic and nondiabetic patients
treated with the BVS. Patient demographics were compa-
rable between diabetic and nondiabetic patients treated with
the BVS, except for a history of hypertension requiring
medication that was more prevalent in diabetic patients
(Table 1). Lesion characteristics were also comparable
between the 2 groups, except for the left anterior descending
artery target lesion location being less prevalent in diabetic
patients. Use of dual antiplatelet therapy did not differ
between the 2 groups at each time point (at discharge,
6 months, and 1 year after the index procedure).
Time-to-event curves showing the cumulative incidence
of DoCE and the components up to 1 year after the index
procedure appear in Figure 2. DoCE at 1 year occurred in
3.7% of diabetic patients and 5.1% of nondiabetic patients
(p ¼ 0.64). There were no signiﬁcant differences in the
incidence of the components up to 1 year of follow-up be-
tween the 2 groups (Table 2). Similarly, PoCE was observed
in 7.4% of diabetic patients and 8.2% of nondiabetic patients(p ¼ 0.86). One patient with diabetes experienced deﬁnite
late ST (0.7%), whereas 1 deﬁnite and 1 probable subacute
ST and 1 deﬁnite late ST (0.7%) were observed in the
nondiabetes group (p ¼ 1.0).
Comparisons between the BVS and EES in diabetic
patients. In the entire study groups with diabetes, the
mean age, rates of hypertension requiring medication, hy-
percholesterolemia requiring medication, diabetes requiring
insulin treatment, family history of CAD, previous coronary
intervention, multivessel disease, type B2/C lesion, lesion
length, reference vessel diameter, and percent of diameter
stenosis were signiﬁcantly greater in the EES group than
in the BVS group. Conversely, male sex, rates of diabetes
requiring oral hypoglycemic agents, unstable angina, and
minimal luminal diameter were signiﬁcantly less in the EES
group (Table 3). After PS matching, all variables became
comparable between the BVS group (102 patients) and the
EES group (172 patients), except for left anterior descend-
ing artery target lesion location being less prevalent in the
BVS group. Use of dual antiplatelet therapy was also com-
parable between the 2 treatment groups.
In the matched study group, DoCE at 1 year occurred
in 3.9% of patients in the BVS group and in 6.4% of patients
in the EES group (p ¼ 0.38) (Fig. 3). There were no sig-
niﬁcant differences in the incidence of each component and
Table 1. Baseline Characteristics of Diabetic and Nondiabetic Patients
Treated With the Absorb BVS
Absorb BVS
Diabetes
(n ¼ 136)
Absorb BVS
Nondiabetes
(n ¼ 415) p Value
Demographic characteristics
Age, yrs 61.6  10.0 (136) 61.9  10.5 (415) 0.81
Male 73.5 (100/136) 73.7 (306/415) 1.00
Current smoker 19.9 (27/136) 21.0 (87/414) 0.81
Hypertension requiring
medication
75.0 (102/136) 61.4 (254/414) 0.004
Hypercholesterolemia
requiring medication
67.6 (92/136) 63.6 (264/415) 0.41
Diabetes treatment
Insulin 16.9 (23/136) 0.0 (0/415) <0.001
Oral hypoglycemic
drugs
74.3 (101/136) 0.0 (0/415) <0.001
Physical exercise and/or
diet modiﬁcation only
4.4 (6/136) 0.0 (0/415) <0.001
No treatment 4.4 (6/136) 100.0 (415/415) <0.001
Family history of coronary
artery disease
41.4 (53/128) 37.2 (148/398) 0.40
Unstable angina 33.8 (46/136) 27.7 (115/415) 0.19
Previous coronary
intervention
23.5 (32/136) 24.6 (102/415) 0.80
Previous myocardial
infarction
26.5 (36/136) 28.8 (119/413) 0.66
Multivessel disease 23.5 (32/136) 17.6 (73/415) 0.13
Target vessel 144 lesions 439 lesions
Right coronary artery 36.8 (53/144) 28.2 (124/439) 0.06
Left anterior descending
artery
36.1 (52/144) 45.8 (201/439) 0.043
Left circumﬂex artery or
ramus
27.1 (39/144) 26.0 (114/439) 0.83
Left main coronary artery 0.0 (0/144) 0.0 (0/439) NA
ACC/AHA lesion class 143 lesions 434 lesions
A/B1 62.9 (90/143) 59.7 (259/434) 0.49
B2/C 37.1 (53/143) 40.3 (175/434) 0.49
Target lesion characteristics 144 lesions 439 lesions
Lesion length, mm 11.7  5.1 (143) 11.2  4.6 (429) 0.25
Pre-procedure
Reference vessel
diameter, mm
2.60  0.33 (143) 2.62  0.37 (429) 0.69
Minimal luminal
diameter, mm
1.07  0.33 (144) 1.08  0.30 (434) 0.79
% Diameter stenosis 58.8  10.8 (144) 58.4  10.3 (433) 0.70
Dual antiplatelet therapy* 136 patients 415 patients
At discharge 100.0 (136/136) 99.5 (413/415) 1.00
At 6 mo 96.3 (131/136) 97.1 (403/405) 0.58
At 1 yr 82.4 (112/136) 82.9 (344/415) 0.90
Values are mean  SD (N) and % (n/N). *Patients taking both aspirin and thienopyridine.
NA ¼ not available; ACC/AHA ¼ American College of Cardiology/American Heart Association;
BVS ¼ bioresorbable vascular scaffold.
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486deﬁnite/probable ST at 1-year follow-up between the 2
treatment groups (Table 4). Similarly, PoCE was observed in
7.8% of the BVS group and in 11.0% of the EES group, where
the difference was not statistically signiﬁcant (p ¼ 0.39).Incidence of adverse events according to diabetes status in
patients treated with the BVS. In the present analysis, the
BVS cohort included 415 nondiabetic patients, and 113
noninsulin-treated and 23 insulin-treated patients with
diabetes. The incidences of DoCE, PoCE, and their com-
ponents at 1 year according to diabetes status are shown in
Figure 4. Insulin-treated diabetic patients tended to have a
higher rate of adverse events compared with nondiabetic
and noninsulin-treated diabetic patients, whereas these dif-
ferences did not reach statistical signiﬁcance (5.1% in no
diabetes, 2.7% in noninsulin-treated diabetes, and 8.7% in
insulin-treated diabetes for DoCE [p ¼ 0.37]; 8.2% in no
diabetes, 7.1% in noninsulin-treated diabetes, and 8.7% in
insulin-treated diabetes for PoCE [p ¼ 0.92]).
Discussion
This is the ﬁrst study addressing the clinical outcomes of
diabetic patients treated with the Absorb BVS. The main
ﬁndings of the present study can be summarized as follows: 1)
there were no signiﬁcant differences in 1-year rates of DoCE,
PoCE, or ST between diabetic and nondiabetic patients
treated with the Absorb BVS; 2) diabetic patients treated with
the Absorb BVS showed 1-year rates of DoCE, PoCE, and
ST similar to the matched diabetic patients treated with EES.
In general, diabetic patients undergoing PCI have an
increased risk of restenosis and ST (10,19,20). Anatomic
complexity of CAD, a phenotype expression of severity and
duration of diabetic syndrome, may show a differential effect
on the clinical outcomes in diabetic patients (21,22). In the
present study, patient demographics and lesion characteris-
tics were nearly identical between diabetic and nondiabetic
patients treated with the BVS, and similar clinical outcomes
were observed up to 1 year of follow-up. Speciﬁcally, the
incidence rates of DoCE (3.7%) and deﬁnite/probable ST
(0.7%) in diabetic patients treated with the BVS were
favorable, although it should be emphasized that the present
study included patients with relatively low risk proﬁles and
noncomplex lesions. In addition, the potential under-
reporting of events related to the speciﬁc monitoring of the
ABSORB EXTEND trial should be noted.
Current therapeutic guidelines recommend DES rather
than BMS for diabetic patients undergoing PCI for
obstructive CAD (23,24). These guidelines, however, rely
on the data derived from ﬁrst-generation DES, showing
considerable risk reduction of restenosis and TLR compared
with BMS (4). Conversely, ﬁrst-generation DES raised
safety concerns regarding an increased risk of very late
ST (25–27). Five-year follow-up data of the LEADERS
(Limus Eluted From A Durable Versus ERodable Stent
Coating) trial indicated that the newer generation biolimus-
eluting stent with biodegradable polymer was associated
with signiﬁcantly lower incidence of PoCE and very late ST
compared with the ﬁrst-generation sirolimus-eluting stent in
Figure 2. Time-to-Event Curves for DoCE and the Components in Diabetic and Nondiabetic Patients Treated With the ABSORB BVS Up to 1-Year Follow-Up
The cumulative incidences of adverse cardiac events are shown separately: DoCE (A), cardiac death (B), target-vessel MI (C), and ID-TLR (D). BVS ¼ bioresorbable
vascular scaffold; DoCE ¼ device-oriented composite endpoint; ID-TLR ¼ ischemia-driven target lesion revascularization; MI ¼ myocardial infarction.
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487the entire study group (9). Although the ESSENCE-
DIABETES (Randomized Comparison of Everolimus-
Eluting Stent Versus Sirolimus-Eluting Stent Implantation
for De Novo Coronary Artery Disease in Patients With
Diabetes Mellitus) trial and the diabetic subgroup analysis of
the RESET (Randomized Evaluation of Sirolimus-eluting
Versus Everolimus-Eluting Stent) trial showed the favorable
trends toward the EES compared with the sirolimus-eluting
stent, no data have supported the superiority of newer
generation DES over ﬁrst-generation DES in diabetic pa-
tients with respect to clinical outcomes (28,29). In the
present analysis, a large number of diabetic patients from
the SPIRIT trials facilitated fair comparisons between
2 different technologies eluting the same antiproliferativedrug everolimus by means of PS matching. One-year DoCE
was observed in 3.9% and 6.4% in the BVS and EES groups,
respectively (p ¼ 0.38). Although this result should be
interpreted with caution due to the limited sample size and
post-hoc analysis nature, our data suggest that the Absorb
BVS is feasible, safe, and effective for the treatment of
diabetic patients with noncomplex lesions.
Insulin and insulin-like growth factors promote stimula-
tory action on vascular smooth muscle cells, which might
result in accelerated smooth muscle cell proliferation
after coronary stenting (30). Everolimus reduces excessive
neointimal hyperplasia by inhibiting the mammalian target of
rapamycin that subsequently interferes with cellular mitosis.
This process is tightly regulated by glycosylation-dependent
Table 2. Clinical Outcomes of Diabetic and Nondiabetic Patients Treated With the Absorb BVS at 1-Year Follow-Up
Outcomes
Absorb BVS:
Diabetic Patients
(N ¼ 136)
Absorb BVS:
Nondiabetic Patients
(N ¼ 415)
p Value% (n/N) 95% CI % (n/N) 95% CI
Device-oriented composite endpoint 3.7 (5/136) 1.2–8.4 5.1 (21/415) 3.2–7.6 0.64
Components (nonhierarchical)
Cardiac death 0.0 (0/136) 0.0–2.7 0.2 (1/415) 0.0–1.3 1.00
Target vessel MI 2.9 (4/136) 0.8–7.4 2.9 (12/415) 1.5–5.0 1.00
Q-wave MI 0.0 (0/136) 0.0–2.7 1.0 (4/415) 0.3–2.5 0.58
Non–Q-wave MI 2.9 (4/136) 0.8–7.4 1.9 (8/415) 0.8–3.8 0.50
ID-TLR 1.5 (2/136) 0.2–5.2 2.4 (10/415) 1.2–4.4 0.74
CABG 0.0 (0/136) 0.0–2.7 0.2 (1/415) 0.0–1.3 1.00
PCI 1.5 (2/136) 0.2–5.2 2.2 (9/415) 1.0–4.1 1.00
Patient-oriented composite endpoint 7.4 (10/136) 3.6–13.1 8.2 (34/415) 5.7–1.3 0.86
Components (nonhierarchical)
All-cause death 0.0 (0/136) 0.0–2.7 0.7 (3/415) 0.2–2.1 1.00
All MI 2.9 (4/136) 0.8–7.4 2.9 (12/415) 1.5–5.0 1.00
Q-wave MI 0.0 (0/136) 0.0–2.7 1.0 (4/415) 0.3–2.5 0.58
Non–Q-wave MI 2.9 (4/136) 0.8–7.4 1.9 (8/415) 0.8–3.8 0.50
Any repeat revascularization 5.1 (7/136) 2.1–10.3 5.1 (21/415) 3.2–7.6 1.00
CABG 0.0 (0/136) 0.0–2.7 0.7 (3/415) 0.2–2.1 1.00
PCI 5.1 (7/136) 2.1–10.3 4.6 (19/415) 2.8–7.1 0.82
Scaffold thrombosis per ARC deﬁnition
Acute, <1 day
Deﬁnite 0.0% (0/136) 0.0–2.7 0.0% (0/415) 0.0–0.9 NA
Probable 0.0% (0/136) 0.0–2.7 0.0% (0/415) 0.0–0.9 NA
Possible 0.0% (0/136) 0.0–2.7 0.0% (0/415) 0.0–0.9 NA
Deﬁnite þ probable 0.0% (0/136) 0.0–2.7 0.0% (0/415) 0.0–0.9 NA
Subacute, 1–30 days
Deﬁnite 0.0 (0/136) 0.0–2.7 0.2 (1/415) 0.0–1.3 1.00
Probable 0.0 (0/136) 0.0–2.7 0.2 (1/415) 0.0–1.3 1.00
Possible 0.0 (0/136) 0.0–2.7 0.0 (0/415) 0.0–0.9 NA
Deﬁnite þ probable 0.0 (0/136) 0.0–2.7 0.5 (2/415) 0.1–1.7 1.00
Late, 31–365 days
Deﬁnite 0.7 (1/136) 0.0–4.0 0.2 (1/414) 0.0–1.3 0.43
Probable 0.0 (0/136) 0.0–2.7 0.0 (0/414) 0.0–0.9 NA
Possible 0.0 (0/136) 0.0–2.7 0.2 (1/414) 0.0–1.3 1.00
Deﬁnite þ probable 0.7 (1/136) 0.0–4.0 0.2 (1/414) 0.0–1.3 0.43
Overall up to 1 yr (0–365 days)
Deﬁnite 0.7 (1/136) 0.0–4.0 0.5 (2/414) 0.1–1.7 0.57
Probable 0.0 (0/136) 0.0–2.7 0.2 (1/414) 0.0–1.3 1.00
Possible 0.0 (0/136) 0.0–2.7 0.2 (1/414) 0.0–1.3 1.00
Deﬁnite þ probable 0.7 (1/136) 0.0–4.0 0.7 (3/414) 0.2–2.1 1.00
ARC ¼ Academic Research Consortium; CABG ¼ coronary artery bypass graft; CI ¼ conﬁdence interval; ID-TLR ¼ ischemia-driven target lesion
revascularization; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; other abbreviations as in Table 1.
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488enzymes in contrast to paclitaxel, which interferes with
multiple cellular processes (31). Indeed, a previous pooled
analysis suggested an interaction between insulin use and
drug type for the incidence of ischemia-driven TLR (10). In
the present study, there were no signiﬁcant differences in the
incidence of DoCE among patients with insulin-treated
diabetes, noninsulin-treated diabetes, and no diabetes treatedwith the BVS. In addition, 1-year rates of DoCE in insulin-
treated diabetic patients were similar between the BVS and
EES (8.7% vs. 8.8%, p ¼ 1.0), although the present study
might be underpowered to elicit small differences due to the
sample size and relatively short follow-up period.
The ARC recommended 2 methodological approaches to
report composite clinical outcomes: DoCE and PoCE. In
Table 3. Baseline Characteristics of Diabetic Patients Before and After Propensity-Score Matching
Before PS Matching After PS Matching
Absorb BVS Diabetes
(n ¼ 136)
EES Diabetes
(n ¼ 882) p Value
Absorb BVS Diabetes
(n ¼ 102)
EES Diabetes
(n ¼ 172) p Value
Demographic characteristics
Age, yrs 61.6  10.0 (136) 63.6  9.9 (882) 0.032 62.2  9.8 (102) 62.2  9.7 (172) 0.97
Male sex 73.5 (100/136) 64.3 (567/882) 0.035 71.6 (73/102) 66.9 (115/172) 0.42
Current smoker 19.9 (27/136) 18.5 (159/859) 0.71 19.6 (20/102) 20.3 (35/172) 0.88
Hypertension requiring medication 75.0 (102/136) 85.6 (754/881) 0.002 84.3 (86/102) 80.2 (138/172) 0.40
Hypercholesterolemia requiring medication 67.6 (92/136) 82.3 (718/872) <0.001 73.5 (75/102) 76.7 (132/172) 0.55
Diabetes treatment
Insulin 16.9 (23/136) 25.7 (227/882) 0.025 18.6 (19/102) 20.9 (36/172) 0.76
Oral hypoglycemic drugs 74.3 (101/136) 59.8 (527/882) 0.001 73.5 (75/102) 65.7 (113/172) 0.23
Physical exercise and/or diet modiﬁcation only 4.4 (6/136) 9.8 (86/882) 0.052 3.9 (4/102) 9.3 (16/172) 0.15
No treatment 4.4 (6/136) 4.8 (42/882) 1.00 3.9 (4/102) 4.1 (7/172) 1.00
Family history of coronary artery disease 41.4 (53/128) 51.1 (377/738) 0.043 45.1 (46/102) 48.8 (84/172) 0.55
Unstable angina 33.8 (46/136) 26.5 (229/864) 0.08 31.4 (32/102) 31.4 (54/172) 1.00
Previous coronary intervention 23.5 (32/136) 34.7 (305/880) 0.010 21.6 (22/102) 31.4 (54/172) 0.08
Previous myocardial infarction 26.5 (36/136) 22.0 (187/849) 0.25 25.5 (26/102) 26.2 (45/172) 0.90
No. of diseased vessels
Multivessel disease 23.5 (32/136) 41.7 (368/882) <0.001 25.5 (26/102) 22.7 (39/172) 0.60
Target vessel 144 lesions 1,035 lesions 108 lesions 183 lesions
Right coronary artery 36.8 (53/144) 28.8 (298/1,035) 0.049 37.0 (40/108) 24.0 (44/183) 0.018
Left anterior descending artery 36.1 (52/144) 41.4 (429/1,035) 0.22 35.2 (38/108) 49.7 (91/183) 0.016
Left circumﬂex artery or ramus 27.1 (39/144) 29.7 (307/1,035) 0.52 27.8 (30/108) 26.2 (48/183) 0.77
Left main coronary artery 0.0 (0/144) 0.1 (1/1,035) 1.00 0.0 (0/108) 0.0 (0/183) NA
ACC/AHA lesion class 143 lesions 1026 lesions 108 lesions 183 lesions
A/B1 62.9 (90/143) 44.5 (457/1,026) <0.001 60.2 (65/108) 55.2 (101/183) 0.41
B2/C 37.1 (53/143) 55.5 (569/1,026) <0.001 39.8 (43/108) 44.8 (82/183) 0.41
Target lesion characteristics 144 lesions 1,035 lesions 108 lesions 183 lesions
Lesion length, mm 11.7  5.1 (143) 15.3  6.6 (1,026) <0.001 12.2  5.2 (108) 12.6  5.2 (183) 0.56
Pre-procedure
Reference vessel diameter, mm 2.60  0.33 (143) 2.74  0.47 (1,029) <0.001 2.62  0.32 (108) 2.64  0.41 (183) 0.62
Minimal luminal diameter, mm 1.07  0.33 (144) 0.77  0.39 (1,033) <0.001 1.04  0.30 (108) 0.99  0.36 (183) 0.28
% diameter stenosis 58.8  10.8 (144) 71.2  12.6 (1,033) <0.001 60.5  9.5 (108) 62.4  10.3 (183) 0.11
Dual antiplatelet therapy*
At discharge 100.0 (136/136) 98.1 (862/879) 0.15 100.0 (102/102) 97.1 (167/172) 0.16
At 6 months 96.3 (131/136) 95.2 (837/879) 0.57 96.1 (98/102) 96.5 (166/172) 1.00
At 1 yr 82.4 (112/136) 81.2 (714/879) 0.75 83.3 (85/102) 79.7 (137/172) 0.45
Values are mean  SD (N) and % (n/N).
EES ¼ everolimus-eluting metal stent; PS ¼ propensity score; other abbreviations as in Table 1.
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489the present analyses, we applied a DoCE as a primary
endpoint because this represents the efﬁciency and efﬁcacy
of a new device. We also reported a PoCE because it rep-
resents the most critical clinical approach and may reﬂect the
systemic risk and beneﬁt for patients related to a new
treatment. In the matched diabetic study group, the 1-year
rate of PoCE was approximately twice as high as that of
DoCE in both the BVS group and the EES group (3.9% for
DoCE vs. 7.8% for PoCE in the BVS group and 6.4% for
DoCE vs. 11.0% for PoCE in the EES group), driven by
non–target lesion revascularizations. This ﬁnding is similar
to those of previous DES studies (32) and highlights theimportance of optimal medical therapies and life-style
modiﬁcation for glycemic control as well as the frequently
accompanying comorbidities such as hypertension, dyslipi-
demia, and obesity if clinical outcomes of diabetic patients
with obstrtrun -1uctive CAD are to be improved (33).
In the most recent report on serial angiographic assess-
ment from the ABSORB Cohort B trial, the in-scaffold late
loss of the BVS increased between 6 months and 1 year,
whereas it remained stable after 1 year (0.16, 0.27, 0.27, and
0.29 mm at 6 months, 1 year, 2 years, and 3 years, respec-
tively) (12,13,34). Conversely, in the SPIRIT II trial, the
in-stent late loss of EES increased from 0.17 mm at
Figure 3. Time-to-Event Curves for DoCE and the Components in the Matched Diabetic Patients Treated With the BVS and in Those Treated With EES
Up to 1-Year Follow-up
The cumulative incidences of adverse cardiac events are shown separately: DoCE (A), cardiac death (B), target-vessel MI (C), and ID-TLR (D). Abbreviations as in
Figures 1 and 2.
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4906 months to 0.33 mm at 2 years (35). In this indirect
comparison, the absolute change in late loss between 6
months and 2 years tended to be smaller with the BVS
(D0.11 mm) than EES (D0.16 mm). More interestingly,
intravascular ultrasound data demonstrated that the EES
lumen volume slightly decreased between 6 months and
2 years in the SPIRIT II trial (159 mm3 at 6 months and
153 mm3 at 2 years), whereas the BVS mean lumen area
signiﬁcantly increased from 1 to 3 years (6.35 mm2 at 1 year
and 6.81 mm2 at 3 years, p < 0.001) in the serial observation
of the ABSORB Cohort B trial (12). This phenomenon can
be explained by the fact that mean and minimal scaffoldareas signiﬁcantly increased and thereby compensated for
neointimal hyperplasia. Therefore, the favorable trend
toward BVS observed in 1-year clinical outcomes in the
present study might become more pronounced with longer
follow-up.
From a physiological perspective, the absence of perma-
nent vessel caging facilitates the restoration of vasomotor
function, adaptive shear stress, cyclic strain, and late luminal
enlargement (11,36). In addition, fewer material triggers for
very late ST such as uncovered struts and durable polymers
would theoretically be present after bioresorption with the
BVS compared with the DES (37). These beneﬁcial effects
Table 4. Clinical Outcomes of Diabetic Patients Treated With BVS and EES at 1-Year Follow-Up
Outcomes
Entire Population Matched Population
Absorb BVS Diabetes
(N ¼ 136)
EES Diabetes
(N ¼ 882)
p Value
Absorb BVS Diabetes
(N ¼ 102)
EES Diabetes
(N ¼ 172)
p Value% (n/N) 95% CI % (n/N) 95% CI % (n/N) 95% CI % (n/N) 95% CI
Device-oriented composite endpoint 3.7 (5/136) 1.2–8.4 6.3 (56/882) 4.9–8.3 0.22 3.9 (4/102) 1.1–9.7 6.4 (11/172) 3.2–11.2 0.38
Components (nonhierarchical)
Cardiac death 0.0 (0/136) 0.0–2.7 1.0 (9/882) 0.5–1.9 0.62 0.0 (0/102) 0.0–3.6 1.2 (2/172) 0.1–4.1 0.53
Target vessel MI 2.9 (4/136) 0.8–7.4 2.7 (24/882) 1.8–4.0 0.78 2.9 (3/102) 0.6–8.4 2.9 (5/172) 1.0–6.7 1.00
Q-wave MI 0.0 (0/136) 0.0–2.7 0.2 (2/882) 0.0–0.8 1.00 0.0 (0/102) 0.0–3.6 1.2 (2/172) 0.1–4.1 0.53
Non–Q-wave MI 2.9 (4/136) 0.8–7.4 2.5 (22/882) 1.6–3.8 0.77 2.9 (3/102) 0.6–8.4 1.7 (3/172) 0.4–5.0 0.67
ID-TLR 1.5 (2/136) 0.2–5.2 3.9 (34/882) 2.7–5.4 0.21 2.0 (2/102) 0.2–6.9 4.1 (7/172) 1.7–8.2 0.49
CABG 0.0 (0/136) 0.0–2.7 0.7 (6/882) 0.3–1.5 1.00 0.0 (0/102) 0.0–3.6 1.2 (2/172) 0.1–4.1 0.53
PCI 1.5 (2/136) 0.2–5.2 3.3 (29/882) 2.2–4.7 0.42 2.0 (2/102) 0.2–6.9 3.5 (6/172) 1.3–7.4 0.71
Patient-oriented composite endpoint 7.4 (10/136) 3.6–13.1 12.4 (109/882) 10.3–14.7 0.09 7.8 (8/102) 3.5–14.9 11.0 (19/172) 6.8–16.7 0.39
Components (nonhierarchical)
All-cause death 0.0 (0/136) 0.0–2.7 1.8 (16/882) 1.0–2.9 0.15 0.0 (0/102) 0.0–3.6 1.2 (2/172) 0.1–4.1 0.53
All MI 2.9 (4/136) 0.8–7.4 2.8 (25/882) 1.8–4.2 1.00 2.9 (3/102) 0.6–8.4 2.9 (5/172) 1.0–6.7 1.00
Q-wave MI 0.0 (0/136) 0.0–2.7 0.2 (2/882) 0.0–0.8 1.00 0.0 (0/102) 0.0–3.6 1.2 (2/172) 0.1–4.1 0.53
Non–Q-wave MI 2.9 (4/136) 0.8–7.4 2.6 (23/882) 1.7–3.9 0.77 2.9 (3/102) 0.6–8.4 1.7 (3/172) 0.4–5.0 0.67
Any repeat revascularization 5.1 (7/136) 2.1–10.3 9.3 (82/882) 7.5–11.4 0.11 5.9 (6/102) 2.2–12.4 9.3 (16/172) 5.4–14.7 0.31
CABG 0.0 (0/136) 0.0–2.7 1.8 (16/882) 1.0–2.9 0.15 0.0 (0/102) 0.0–3.6 2.9 (5/172) 1.0–6.7 0.16
PCI 5.1 (7/136) 2.1–10.3 7.7 (68/882) 6.0–9.7 0.29 5.9 (6/102) 2.2–12.4 7.0 (12/172) 3.7–11.9 0.72
SST per ARC deﬁnition
Acute, <1 day
Deﬁnite 0.0 (0/136) 0.0–2.7 0.2 (2/882) 0.0–0.8 1.00 0.0 (0/102) 0.0–3.6 0.6 (1/172) 0.0–3.2 1.00
Probable 0.0 (0/136) 0.0–2.7 0.0 (0/882) 0.0–0.4 NA 0.0 (0/102) 0.0–3.6 0.0 (0/172) 0.0–2.1 NA
Possible 0.0 (0/136) 0.0–2.7 0.0 (0/882) 0.0–0.4 NA 0.0 (0/102) 0.0–3.6 0.0 (0/172) 0.0–2.1 NA
Deﬁnite + probable 0.0 (0/136) 0.0–2.7 0.2 (2/882) 0.0–0.8 1.00 0.0 (0/102) 0.0–3.6 0.6 (1/172) 0.0–3.2 1.00
Subacute, 1–30 days
Deﬁnite 0.0 (0/136) 0.0–2.7 0.1 (1/882) 0.0–0.6 1.00 0.0 (0/102) 0.0–3.6 0.0 (0/172) 0.0–2.1 NA
Probable 0.0 (0/136) 0.0–2.7 0.0 (0/882) 0.0–0.4 NA 0.0 (0/102) 0.0–3.6 0.0 (0/172) 0.0–2.1 NA
Possible 0.0 (0/136) 0.0–2.7 0.0 (0/882) 0.0–0.4 NA 0.0 (0/102) 0.0–3.6 0.0 (0/172) 0.0–2.1 NA
Deﬁnite + probable 0.0 (0/136) 0.0–2.7 0.1 (1/882) 0.0–0.6 1.00 0.0 (0/102) 0.0–3.6 0.0 (0/172) 0.0–2.1 NA
Late, 31–365 days
Deﬁnite 0.7 (1/136) 0.0–4.0 0.5 (4/874) 0.1–1.2 0.52 1.0 (1/102) 0.0–5.3 1.2 (2/172) 0.1–4.1 1.00
Probable 0.0 (0/136) 0.0–2.7 0.2 (2/874) 0.0–0.8 1.00 0.0 (0/102) 0.0–3.6 0.0 (0/172) 0.0–2.1 NA
Possible 0.0 (0/136) 0.0–2.7 0.7 (6/874) 0.3–1.5 1.00 0.0 (0/102) 0.0–3.6 1.2 (2/172) 0.1–4.1 0.53
Deﬁnite + probable 0.7 (1/136) 0.0–4.0 0.7 (6/874) 0.3–1.5 1.00 1.0 (1/102) 0.0–5.3 1.2 (2/172) 0.1–4.1 1.00
Overall up to 1 yr (0–365 days)
Deﬁnite 0.7 (1/136) 0.0–4.0 0.8 (7/874) 0.3–1.6 1.00 1.0 (1/102) 0.0–5.3 1.7 (3/172) 0.4–5.0 1.00
Probable 0.0 (0/136) 0.0–2.7 0.2 (2/874) 0.0–0.8 1.00 0.0 (0/102) 0.0–3.6 0.0 (0/172) 0.0–2.1 NA
Possible 0.0 (0/136) 0.0–2.7 0.7 (6/874) 0.3–1.5 1.00 0.0 (0/102) 0.0–3.6 1.2 (2/172) 0.1–4.1 0.53
Deﬁnite + probable 0.7 (1/136) 0.0–4.0 1.0 (9/874) 0.5–2.0 1.00 1.0 (1/102) 0.0–5.3 1.7 (3/172) 0.4–5.0 1.00
ST ¼ scaffold/stent thrombosis; other abbreviations as in Tables 1 to 3.
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491of the BVS, however, are not expected to be evident until
after 1 year. Therefore, longer clinical follow-up is needed to
elucidate the differential consequences of the Absorb BVS
from a permanent metal prosthesis, in particular, for the
diabetic patients.
Study limitations. First, the present analysis included
noncomplex lesions according to pre-speciﬁed trial protocols.Therefore, the clinical performance of the BVS in diabetic
patients with complex lesions (e.g., diffuse lesion and calciﬁed
lesion) is still unknown. Second, despite the PS matching
to allow fair comparisons between the BVS and the EES,
the possibility of results being affected by unknown con-
founding factors cannot be excluded. Third, our results
should be considered hypothesis generating due to the
Figure 4. 1-Year Rates of Adverse Cardiac Events According to Diabetes Status in Patients Treated With the Absorb BVS
The 1-year rates of DoCE and the components (A) and those of PoCE and the components (B). PoCE ¼ patient-oriented composite endpoint; other abbreviations as in
Figure 2.
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492nonrandomized, post-hoc nature of the analyses. In ad-
dition, the present analyses might be underpowered to
demonstrate the differences of clinical efﬁcacy between the
devices. Further investigation is thus required in large-scale,
randomized, controlled trials for a pre-speciﬁed diabetic
study group.Conclusions
In this ﬁrst report of the Absorb BVS in diabetic patients,
the 1-year incidence rate of DoCE was 3.7%, similar to that
in nondiabetic patients. In addition, no differences in the
rates of 1-year DoCE, PoCE, or ST were observed in dia-
betic patients treated with the Absorb BVS and the
XIENCE V EES in the matched study group from pooled
prospective trials. These promising results should stimulate
future trials of the Absorb BVS in larger cohorts of diabeticpatients with both complex and noncomplex lesions with
long-term follow-up to demonstrate whether clinical ad-
vantages are present with this novel technology.
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